Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
FAMS - Bothered by Chills	NCIT_C112606	[Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am bothered by the chills.]
FAMS - Bothered by Fevers	NCIT_C112607	[Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am bothered by fevers (episodes of high body temperature).]
Melanoma of the Conjunctiva cT3a TNM Finding v7	NCIT_C88653	[Melanoma of the conjunctiva invading the globe. (from AJCC 7th Ed.)]
Melanoma of the Conjunctiva cT3 TNM Finding v7	NCIT_C88652	[Melanoma of the conjunctiva with local invasion. (from AJCC 7th Ed.)]
FAMS - I Feel Nervous	NCIT_C112600	[Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I feel nervous.]
Melanoma of the Conjunctiva cT3b TNM Finding v7	NCIT_C88654	[Melanoma of the conjunctiva invading the eyelid. (from AJCC 7th Ed.)]
FAMS - Worry My Condition Will Get Worse	NCIT_C112601	[Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I worry that my condition will get worse.]
Melanoma of the Conjunctiva cT3c TNM Finding v7	NCIT_C88655	[Melanoma of the conjunctiva invading the orbit. (from AJCC 7th Ed.)]
FAMS - I Am Sleeping Well	NCIT_C112602	[Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: I am sleeping well.]
Melanoma of the Conjunctiva cT3d TNM Finding v7	NCIT_C88656	[Melanoma of the conjunctiva invading a sinus. (from AJCC 7th Ed.)]
FAMS - Heat Worsens My Symptoms	NCIT_C112603	[Functional Assessment of Multiple Sclerosis (FAMS) Additional Concerns: Heat worsens my symptoms.]
Carotuximab	NCIT_C74010	[A human/murine chimeric monoclonal antibody directed against endoglin (CD105) with potential antiangiogenic and antineoplastic activities. Carotuximab binds to endoglin, which may result in inhibition of tumor angiogenesis and decreased tumor cell proliferation. The glycoprotein endoglin is a transforming growth factor beta-1 (TGF beta-1) accessory receptor that is highly expressed on tumor vessel endothelial cells and appears to be essential for angiogenesis.]
Dalotuzumab	NCIT_C74011	[A recombinant humanized monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF1R) with potential antineoplastic activity. Dalotuzumab binds to membrane-bound IGF1R, preventing binding of the ligand IGF1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. The activation of IGF1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF1R signaling has been highly implicated in tumorigenesis and metastasis.]
Anti-CD30 Monoclonal Antibody XmAb2513	NCIT_C74005	[A humanized monoclonal antibody directed against the cell surface receptor CD30 with potential immunotherapeutic activity. Anti-CD30 monoclonal antibody XmAb2513 specifically binds to the CD30 antigen, which may result in a cytotoxic T lymphocyte (CTL) response against CD30-expressing tumor cells. CD30, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on activated lymphocytes transiently and is constitutively expressed in hematologic malignancies including Hodgkin's disease and some T-cell non-Hodgkin's lymphomas.]
Otlertuzumab	NCIT_C74006	[A recombinant single-chain polypeptide engineered to exhibit the full binding and activity of an anti-CD37 monoclonal antibody with potential immunostimulatory and antineoplastic activities. Otlertuzumab binds to CD37 on B-cells, which may result in antibody-dependent cell-mediated cytotoxicity (ADCC) and apoptosis. CD37 is a transmembrane glycoprotein expressed at high-levels on B cells and to a lesser extent on T cells and myeloid cells. This agent may have a longer half-life in vivo than conventional monoclonal antibodies.]
Daratumumab	NCIT_C74007	[A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 with potential antineoplastic activity. The binding of anti-CD38 monoclonal antibody to natural killer (NK) cells mimics the normal CD38-CD31 interaction on the NK cell surface. CD38 is also present on multiple myeloma (MM) cells and plasma leukemia cells; this agent may preferentially bind these cells, triggering antitumoral antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). CD38, a cell surface glycoprotein, is present on various immune cells and has been shown to regulate the cytotoxic response of activated NK cells.]
Anti-CD38 Monoclonal Antibody	NCIT_C155321	[Any monoclonal antibody that is directed against the CD38 antigen.]
CD40 Agonist Monoclonal Antibody CP-870,893	NCIT_C74008	[A fully human monoclonal antibody (mAb) agonist of the cell surface receptor CD40 with potential immunostimulatory and antineoplastic activities. Similar to the CD40 ligand (CD40L or CD154), CD40 agonist monoclonal antibody CP-870,893 binds to CD40 on a variety of immune cell types, triggering the cellular proliferation and activation of antigen-presenting cells (APCs), activating B cells and T cells, and enhancing the immune response; in addition, this agent may activate CD40 present on the surfaces of some solid tumor cells, resulting in apoptosis and decreased tumor growth. CD40, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on various immune cells, many B-cell malignancies, and some solid tumors, mediating both indirect tumor cell killing through the activation of the immune system and direct tumor cell apoptosis.]
Anti-CD40 Monoclonal Antibody	NCIT_C133877	[Any monoclonal antibody directed against the antigen cluster of differentiation 40 (CD40).]
Tiomolibdate Diammonium	NCIT_C74001	[An ammonium salt with potential antiangiogenic and antitumor activities. Tetrathiomolybdate has been found to deplete systemic copper reserves through an unknown mechanism. This agent has been shown to inhibit the activities of cuproenzymes, including superoxide dismutase 1 (SOD1) and cytochrome c oxidase (COX), which may contribute to its antiangiogenic and antitumor effects.]